Search
Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19344ApprovedInvestigationalpneumoniae_ serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197). … Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains de-O-acetylated saccharides of the capsular antigens of _Streptococcus
Enristomig
go.drugbank.com/drugs/DB29060InvestigationalINBRX-105 is a biologic drug. … INBRX-105 is under investigation in clinical trial NCT03809624 (Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer).
Aminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnIn the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.
Synonyms: N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acidPhosphatidylcholine Biosynthesis PC(15:0/18:4(6Z,9Z,12Z,15Z))
smpdb.ca/view/SMP0014285MetabolicPhosphatidylcholines (PC) are a class of phospholipids that incorporate a phosphocholine headgroup into a diacylglycerol backbone. They are the most abundant phospholipid in eukaryotic cell membranes and has both structural and signallin...
Drugs: Ademetionine · Choline · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium +2 morePhosphatidylethanolamine Biosynthesis PE(15:0/18:4(6Z,9Z,12Z,15Z))
smpdb.ca/view/SMP0015125MetabolicPhosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...
Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 morePhosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/15:0)
smpdb.ca/view/SMP0015376MetabolicPhosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...
Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 moreDe Novo Triacylglycerol Biosynthesis TG(15:0/18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))
smpdb.ca/view/SMP0017479MetabolicA triglyceride (TG, triacylglycerol, TAG, or triacylglyceride) is an ester derived from glycerol and three fatty acids. Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. They are a...
MF-300
go.drugbank.com/drugs/DB32060InvestigationalMF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase. … As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]
Protein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalProtein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. … APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETPozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigationalCD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. … [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.